Skip to main content
SpringerLink
Log in

Role of Hematopoietic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma

  • Chapter
  • First Online:
Hematopoietic Stem Cell Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 144))

  • 1457 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  2. Feugier P, Van Hoof A, Sebban A, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.

    Article  PubMed  CAS  Google Scholar 

  3. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23.

    Article  PubMed  CAS  Google Scholar 

  4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

    Article  PubMed  CAS  Google Scholar 

  5. Pasquini M. Part I-CIBMTR summary slides, 2005. CIBMTR Newsl. 2006;12:5–8.

    Google Scholar 

  6. Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007;39:71–87.

    Article  PubMed  CAS  Google Scholar 

  7. Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–98.

    Article  PubMed  CAS  Google Scholar 

  8. Butcher BW, Collins RH. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant. 2005;36:1–17.

    Article  PubMed  CAS  Google Scholar 

  9. Baron F, Storb R. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Pract Res Clin Haematol. 2006;19:637–53.

    Article  PubMed  CAS  Google Scholar 

  10. Shipp MA. Prognostic factors in non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 1994;83:1165–73.

    PubMed  CAS  Google Scholar 

  11. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–96.

    Article  PubMed  CAS  Google Scholar 

  12. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–91.

    Article  PubMed  CAS  Google Scholar 

  13. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant. 2006;38:715–20.

    Article  PubMed  CAS  Google Scholar 

  14. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008;111:446–52.

    Article  PubMed  CAS  Google Scholar 

  15. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin’s disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2000;29:303–12.

    Article  Google Scholar 

  16. Oehler-Jänne C, Taverna C, Stanek N, et al. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma: a case-control study. Hematol Oncol. 2007;Published Online Dec 17, 2007.

    Google Scholar 

  17. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19:406–13.

    PubMed  CAS  Google Scholar 

  18. Friedberg JW, Neuberg D, Monson J, et al. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2001;7:446–53.

    Article  PubMed  CAS  Google Scholar 

  19. Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin’s lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 2000;6:506–12.

    Article  PubMed  CAS  Google Scholar 

  20. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant. 2007;39:577–88.

    Article  PubMed  CAS  Google Scholar 

  21. Robertson MJ, Abonour R, Hromas R, et al. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2005;46:1477–87.

    Article  PubMed  CAS  Google Scholar 

  22. Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47:1488–94.

    Article  PubMed  Google Scholar 

  23. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770–7.

    Article  PubMed  CAS  Google Scholar 

  24. Betticher DC, Martinelli G, Radford JA, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006;17:1546–52.

    Article  PubMed  CAS  Google Scholar 

  25. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533–8.

    Article  PubMed  CAS  Google Scholar 

  26. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–7.

    Article  PubMed  CAS  Google Scholar 

  27. Olivieri A, Santini G, Patti C, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941–8.

    Article  PubMed  CAS  Google Scholar 

  28. Haioun C, Mounier N, Quesnel B, et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. Ann Oncol. 2001;12:1749–55.

    Article  PubMed  CAS  Google Scholar 

  29. Ahmed T, Rashid K, Waheed F. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma. 2005;46:405–14.

    Article  PubMed  CAS  Google Scholar 

  30. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:3918–24.

    PubMed  CAS  Google Scholar 

  31. Gutman JA, Bearman SI, Nieto Y, et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant. 2005;36:443–51.

    Article  PubMed  CAS  Google Scholar 

  32. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003;102:2351–7.

    Article  PubMed  CAS  Google Scholar 

  33. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–7.

    Article  PubMed  CAS  Google Scholar 

  34. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:90–5.

    Article  PubMed  CAS  Google Scholar 

  35. Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant. 2006;12:697–702.

    Article  PubMed  CAS  Google Scholar 

  36. Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol. 2007;86:107–15.

    Article  PubMed  CAS  Google Scholar 

  37. Tarella C, Zanni M, Nicola MD, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007;21:1802–11.

    Article  PubMed  CAS  Google Scholar 

  38. van Heeckeren WJ, Wollweiler J, Fu P, et al. Randomized comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. Br J Haematol. 2005;132:42–55.

    Article  Google Scholar 

  39. Bierman PJ, Sweetenham JW, Loberiza FR, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003:21:3744–53.

    Article  PubMed  Google Scholar 

  40. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521–9.

    Article  PubMed  CAS  Google Scholar 

  41. Brown JR, Feng Y, Gribben JG, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13:1057–65.

    Article  PubMed  Google Scholar 

  42. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–27.

    Article  PubMed  CAS  Google Scholar 

  43. Jacobsen E, Freedman A. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol. 2004;5:711–7.

    Article  PubMed  CAS  Google Scholar 

  44. Imai Y, Chou T, Kobinai K, et al. Isolation and transplantation of high purified CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin’s lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant. 2005;35:479–87.

    Article  PubMed  CAS  Google Scholar 

  45. Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study. Ann Oncol. 2004;15:504–10.

    Article  PubMed  CAS  Google Scholar 

  46. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777–83.

    Article  PubMed  CAS  Google Scholar 

  47. Brugger W, Hirsch J, Grünebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15:1691–8.

    Article  PubMed  CAS  Google Scholar 

  48. Holmberg LA, Maloney D, Bensinger W. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma. 2006;7:135–9.

    Article  PubMed  CAS  Google Scholar 

  49. Bolaños-Meade J, Garrett-Mayer E, Luznik L, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007;13:1185–91.

    Article  PubMed  CAS  Google Scholar 

  50. Caballero MD, Pérez-Simón JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2003;14:140–51.

    Article  PubMed  CAS  Google Scholar 

  51. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;110:116–27.

    Article  Google Scholar 

  52. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–8.

    Article  PubMed  CAS  Google Scholar 

  53. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:4561–6.

    Article  PubMed  CAS  Google Scholar 

  54. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl. 4:iv31–2.

    Article  PubMed  Google Scholar 

  55. Blay JY, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998;92:3562–68.

    PubMed  CAS  Google Scholar 

  56. Lerner RE, Thomas W, DeFor TE, et al. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin’s lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 2007;13:486–92.

    Article  PubMed  Google Scholar 

  57. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-flurodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53–59.

    Article  PubMed  CAS  Google Scholar 

  58. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110:1361–9.

    Article  PubMed  Google Scholar 

  59. Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004;15:1504–9.

    Article  PubMed  CAS  Google Scholar 

  60. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol—A Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–30.

    PubMed  CAS  Google Scholar 

  61. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–95.

    Article  PubMed  CAS  Google Scholar 

  62. Greb A, Bohlius J, Trelle S, et al. High dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev. 2007;33:338–46.

    Article  PubMed  CAS  Google Scholar 

  63. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2003;9:667.

    Article  PubMed  Google Scholar 

  64. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131:223–30.

    Article  PubMed  Google Scholar 

  65. Kim SW, Tanimoto TE, Hirabayashi N, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma: a nationwide survey in Japan. Blood 2006;108:382–9.

    Article  PubMed  CAS  Google Scholar 

  66. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–78.

    Article  PubMed  CAS  Google Scholar 

  67. Aksentijevich I, Jones RJ, Ambinder RF, et al. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:965–72.

    Article  PubMed  Google Scholar 

  68. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–6.

    Article  PubMed  CAS  Google Scholar 

  69. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744–8.

    Article  PubMed  CAS  Google Scholar 

  70. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007;21:2316–23.

    Article  PubMed  CAS  Google Scholar 

  71. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428–34.

    Article  PubMed  CAS  Google Scholar 

  72. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloabative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:1326–34.

    Article  PubMed  Google Scholar 

  73. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000;11:1585–90.

    Article  PubMed  CAS  Google Scholar 

  74. Vignot S, Mounier N, Larghero J, et al. High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. Cancer 2007;109:60–7.

    Article  PubMed  CAS  Google Scholar 

  75. Laudi N, Arora M, Burns LJ, et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:129–35.

    Article  PubMed  Google Scholar 

  76. Sabloff M, Atkins HL, Bence-Bruckler I, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant. 2007:13;956–64.

    Article  PubMed  Google Scholar 

  77. Vose JM, Bierman PJ, Loberiza FR, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008;14:36–42.

    Article  PubMed  Google Scholar 

  78. Rohatiner AZS, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554–9.

    Article  PubMed  Google Scholar 

  79. Montoto S, Canals C, Rohatiner AZS, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007;21:2324–31.

    Article  PubMed  CAS  Google Scholar 

  80. Krishnan A, Nademanee A, Fung H, et al. Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation? Biol Blood Marrow Transplant. 2006;12:641–7.

    Article  PubMed  Google Scholar 

  81. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667–74.

    Article  PubMed  CAS  Google Scholar 

  82. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005;105:3817–23.

    Article  PubMed  CAS  Google Scholar 

  83. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006;108:2540–4.

    Article  PubMed  CAS  Google Scholar 

  84. Bolwell B, Kalaycio M, Andresen S, et al. Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma. Clin Lymphoma. 2000;3:226–31.

    Article  Google Scholar 

  85. Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19:727–35.

    PubMed  CAS  Google Scholar 

  86. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:211–7.

    Article  PubMed  Google Scholar 

  87. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998;92:1832–6.

    PubMed  Google Scholar 

  88. Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol. 2004;127:311–21.

    Article  PubMed  Google Scholar 

  89. Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:737–44.

    Article  PubMed  CAS  Google Scholar 

  90. Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007;92:627–34.

    Article  PubMed  Google Scholar 

  91. van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006;20:235–44.

    Article  PubMed  CAS  Google Scholar 

  92. Vandenberghe E, Ruiz de Elvira C, Loberiza F, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120;793–800.

    Article  PubMed  Google Scholar 

  93. Kasamon YL, Jones RJ, Diehl LF, et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2005;11:39–46.

    Article  PubMed  Google Scholar 

  94. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol. 2005;16:618–24.

    Article  PubMed  CAS  Google Scholar 

  95. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–9.

    PubMed  CAS  Google Scholar 

  96. Mangel J. Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol. 2004;15:283–90.

    Article  PubMed  CAS  Google Scholar 

  97. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749–55.

    Article  PubMed  CAS  Google Scholar 

  98. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–84.

    Article  PubMed  CAS  Google Scholar 

  99. Khouri IF, Lee MS, Romaguera J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999:10:1293–9.

    Article  PubMed  CAS  Google Scholar 

  100. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535–42.

    Article  PubMed  CAS  Google Scholar 

  101. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407–12.

    Article  PubMed  CAS  Google Scholar 

  102. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443–50.

    Article  PubMed  CAS  Google Scholar 

  103. Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405–10.

    Article  PubMed  CAS  Google Scholar 

  104. Rodríguez J, Caballero MD, Gutiérrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768–75.

    Article  PubMed  Google Scholar 

  105. Blystad AK, Enblad G, Kvaløy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711–6.

    Article  PubMed  CAS  Google Scholar 

  106. Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978–85.

    Article  PubMed  Google Scholar 

  107. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134:202–7.

    Article  PubMed  Google Scholar 

  108. Fanin R, Ruiz de Elvira MC, Sperotto A, et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma; analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;23:437–42.

    Article  PubMed  CAS  Google Scholar 

  109. Jagasia M, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma. 2004;45:2261–7.

    Article  PubMed  CAS  Google Scholar 

  110. Mounier N, Gisselbrecht C, Brière J, et al. Prognostic factors in patients with aggressive non-Hodgkin’s lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2004;22:2826–34.

    Article  PubMed  CAS  Google Scholar 

  111. Mounier N, Gisselbrecht C, Brière J, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis from the Groupe d’Etude des lymphomas de l’Adulte (GELA). Ann Oncol. 2004;15:1790–7.

    Article  PubMed  CAS  Google Scholar 

  112. Rodríguez J, Conde E, Gutiérrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652–7.

    Article  PubMed  Google Scholar 

  113. Reimer P, Rüdiger T, Wilhelm W. The role of high-dose therapy in peripheral T-cell lymphomas. Clin Lymphoma Myeloma. 2006;6:373–9.

    Article  PubMed  Google Scholar 

  114. Rodríguez, J, Conde E, Gutiérrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79:32–8.

    Article  PubMed  Google Scholar 

  115. Kahl C, Leithäuser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol. 2002;81:646–50.

    Article  PubMed  CAS  Google Scholar 

  116. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22;2172–6.

    Article  PubMed  Google Scholar 

  117. Wulf GG, Hasenkamp J, Jung W, et al. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2005;36:271–3.

    Article  PubMed  CAS  Google Scholar 

  118. Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–9.

    Article  PubMed  Google Scholar 

  119. Mielcarek M, Storer BE, Flowers ME, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1160–8.

    Article  PubMed  Google Scholar 

  120. Jantunen E, Itälä M, Siitonen T, et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Eur J Haematol. 2006;77:114–9.

    Article  PubMed  CAS  Google Scholar 

  121. Socié G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373–85.

    Article  PubMed  CAS  Google Scholar 

  122. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12:138–51.

    Article  PubMed  Google Scholar 

  123. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21:897–906.

    Article  PubMed  Google Scholar 

  124. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999;94:1814–9.

    PubMed  CAS  Google Scholar 

  125. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:2208–14.

    Article  PubMed  CAS  Google Scholar 

  126. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904.

    Article  PubMed  CAS  Google Scholar 

  127. Shimada K, Yokozawa T, Atsuta Y, et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant. 2005;36:115–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Oncology-Hematology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA

    Philip J. Bierman

Authors
  1. Philip J. Bierman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon L. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip J. Bierman .

Editor information

Editors and Affiliations

  1. Weeping Cherry Drive 14015 , Rockville, 20850, U.S.A.

    Michael R. Bishop

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bierman, P.J., Phillips, G.L. (2009). Role of Hematopoietic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma. In: Bishop, M. (eds) Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 144. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78580-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-78580-6_15

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-78579-0

  • Online ISBN: 978-0-387-78580-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation